PODCAST · business
The Readout Loud
by STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
-
417: Hospitals' next lucrative bet — longevity clinics
Longevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work? On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on STAT reporter Sarah Todd to discuss the booming industry of longevity health and her visit...
-
416: NIH funding uncertainty thwarts U.S. researchers
How has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on STAT reporter Anil Oza and...
-
415: Mistrust in science and a juicy gene-editing lawsuit
On this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko about the impact of Americans’ growing skepticism of science. Your co-hosts also...
-
The FDA's Overton era, and dispatches from Shanghai
"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also speak to colleague Margaret Manto about Heidi Overton, the president's pick to…
more -
Definium's new psychedelics data, and a reprieve for international scientists
International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this week's episode of...
-
Why two promising heart drugs flopped and what's next
On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development of new heart medicines moving forward? Cardiologist and...
-
411: Capricor's data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s…
more -
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Readout LOUD,”…
more -
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. Soon, you’ll be...
-
408: Whistleblower takes on health insurance and FDA commissioner candidates
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s...
-
407: The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our...
-
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene therapy for Huntington’s disease, clearing a path for its maker, the biotech…
more -
405: An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s...
-
404: What RevMed's pancreatic cancer drug meant for one patient
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches? We discuss all that and more on this week's episode of “The...
-
403: Biotech exec Jeremy Levin on the industry's strategic turning point
On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist, and it is in some respects, but as Levin explains, the book is also a roadmap…
more -
402: Guarding biotech from China and big bets in longevity
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar's comments that the company is...
-
401: Makary’s departure and Cassidy’s tenuous Senate seat
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about his acting replacement, Kyle Diamantas. Washington correspondent Chelsea...
-
400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles
On this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including the obesity pill battle between Eli Lilly and Novo Nordisk, a Phase 3 study win...
-
399: Hair-raising trial results, and Servier’s M&A wishlist
Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast....
-
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly...
-
397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
On this week’s episode of the Readout LOUD: a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in lymphoma. Your favorite biotech podcasting crew is back to full strength this week, and we’re bringing you two newsy guest interviews. First, we’ll talk with Allogene...
-
396: A new trick for old science, and biotech VCs' scrambled playbook
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also...
-
395: Biotech investors' plea to Trump, and a busy M&A week
How has the Food and Drug Administration's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? And where did Allison go on her vacation? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's weekly biotech...
-
394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
On this week’s episode of "The Readout LOUD": Allison DeAngelis is still away, leaving Elaine Chen and Adam Feuerstein to mind the podcasting store. You've been warned. Eli Lilly’s deal man Jake van Naarden is very, very busy, so what does that mean for biotech and pharma? Speaking of deals…
more -
393: A conversation with the 'godfather' of biotech
On this week's episode of "The Readout LOUD," we bring you a special conversation with Stelios Papadapolous, also know as the "godfather" of biotech. He sat down for an on-stage chat with our colleague Damian Garde Thursday afternoon during STAT’s Breakthrough Summit East event in New York City.…
more -
392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
How was a known friend of Jeffrey Epstein able to raise $100 million, with the help of a prominent biotech VC? And will Vinay Prasad return to the Food and Drug Administration for a "three-peat"? Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a...
-
391: Breaching the IBD efficacy ceiling, and sham surgeries
Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments? Spyre Therapeutics CEO Cameron Turtle joins the podcast to discuss his company's experimental IBD medications,...
-
390: FDA turmoil, election intrigue, AI, and more
On "The Readout LOUD" this week: Adam Feuerstein, solo. His usual co-hosts Allison DeAngelis and Elaine Chen took some time off, so Adam manned the podcast mic himself. Adam thought, quite understandably, that our cherished listeners wouldn’t want to hear him drone on for 30 minutes, so he...
-
389: Hims' Super Bowl fallout, and the FDA reverses course
Was Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening behind-the-scenes with Moderna and the Food and Drug Administration? We discuss all that on this week's episode of "The Readout LOUD." STAT's Katie Palmer joins Adam,...
-
388: The FDA's refusal to review Moderna's mRNA flu vaccine
We’re devoting our entire episode this week to one controversial and impactful topic: the FDA’s decision to block the review of Moderna’s mRNA flu shot. STAT was the first to report that Vinay Prasad, the agency’s top regulator of vaccines, overruled the head of the FDA’s vaccine office and other...
-
387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial...
-
From Drug Story: Lipitor and Heart Disease
This is an episode of Drug Story, a podcast by Thomas Goetz. You can find the rest of the series at https://www.drugstory.co/podcast Once you turn 40, it seems like half the people you know are taking a statin drug. You know, because their cholesterol is high, and to prevent heart disease down…
more -
386: The high stakes for Huntington's patients
Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington's disease, and the outcome could be potentially devastating for patients. That's what patient advocate Lauren Holder says on the latest episode of “The...
-
385: A measles outbreak and hospitals' financial troubles
Why is the U.S. at risk of losing its measles elimination status? How are health officials reacting to the measles outbreak? And what did top Centers for Medicare and Medicaid Services official Mehmet Oz tell hospital executives at a fancy yacht party in San Francisco? We discuss all that and…
more -
384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
For this very special episode of The Readout LOUD Allison, Adam, and Elaine are live from the J.P. Morgan Healthcare Conference in San Francisco. The hosts are joined by ARCH Venture Partners co-founder and managing director Bob Nelsen and new Novo Nordisk CEO Mike Doustdar joins the podcast…
more -
383: JPM to bring more deals and happy CEOs
What news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. We bring on former co-host Damian Garde, who’s...
-
382: Biotech's year in review
Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at...
-
381: The future of American science and a dispatch from ASH
How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health? First, we...
-
380: A new top drug regulator and the future of psychedelics
On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news. Our special guest this week is David Olson, director...
-
379: How Mark Cuban plans to ‘f— up’ health care
How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting? We discuss all that and more on this…
more -
378: Merck's heart disease win and the FDA's new drug regulator
What does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li, the head of R&D at Merck, joins us to discuss the long-awaited trial results for the company's...
-
377: Melodrama at the FDA and the Pfizer-Novo bidding war
On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence about a slow-boiling feud between Vinay Prasad, the head of the FDA’s biologics and vaccine branch, and his staff that has triggered even more exits and plunging…
more -
376: BridgeBio’s great week and Moderna’s unraveling
Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss…
more -
375: Startups push the FDA and biotech booms in North Carolina
Can Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit? We discuss all that and more in the latest episode of "The Readout LOUD."Elaine is out this week, so Adam and Allison dive into the…
more -
374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market
On this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquired one of Meanwell’s companies, the obesity drug developer Metsera, for just under $5 billion. Meanwell offered his perspectives on the evolving...
-
373: Party in biotech land and AstraZeneca’s miscalculation
Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care strategist Jared Holz to...
-
372: A pharma C-suite shakeup and Trump's deal with Pfizer
How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?Adam is out this week, so Allison and Elaine dive into the latest news, starting with...
-
371: A gene therapy success in Huntington's and Trump's autism announcement
We bring on UniQure CEO Matt Kapusta to discuss the company's announcement this week that its one-time treatment for Huntington’s disease significantly slowed down the neurological condition in a key study. We also chat about the Trump's administration initiatives on autism. Officials this week...
-
370: Pharma sours on the U.K., plus biotech M&A's quiet roll
STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere. We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $3.5 billion...
-
369: Trump, Chinese biotech, and an industry career reshaped by illness
Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week, he penned a poignant personal essay explaining how some medical setbacks have impacted his professional life. He joins us to discuss. But first, President…
more
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
HOSTED BY
STAT
CATEGORIES
Loading similar podcasts...
Frequently Asked Questions
How many episodes does The Readout Loud have?
The Readout Loud currently has 422 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is The Readout Loud about?
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
How often does The Readout Loud release new episodes?
The Readout Loud publishes regularly with 422 episodes available. Check the episode list for the typical release schedule.
Where can I listen to The Readout Loud?
You can listen to The Readout Loud on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts The Readout Loud?
The Readout Loud is created and hosted by STAT.
URL copied to clipboard!